Bioptik TechnologyROCO:4161 68 Market Cap is NT$1,375.6 Mil as of Jul. 12, 2026. GuruFocus rates ROCO:4161 with a GF Score™ of 68/100 and a GF Value™ of NT$27.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 866 Medical Devices & Instruments companies, Bioptik Technology ranks worse than 64.2% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bioptik Technology's share price for the quarter that ended in Dec. 2025 was NT$24.95. Bioptik Technology's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 59.8 Mil. Therefore, Bioptik Technology's market cap for the quarter that ended in Dec. 2025 was NT$1,492.2 Mil.
Bioptik Technology's quarterly market cap
increased
from Jun. 2025 (NT$1,585.6 Mil) to Sep. 2025 (NT$1,713.5 Mil) but then
declined
from Sep. 2025 (NT$1,713.5 Mil) to Dec. 2025 (NT$1,492.2 Mil).
Bioptik Technology's annual market cap
declined
from Dec. 2023 (NT$1,703.3 Mil) to Dec. 2024 (NT$1,627.9 Mil) and
declined
from Dec. 2024 (NT$1,627.9 Mil) to Dec. 2025 (NT$1,492.2 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bioptik Technology's Enterprise Value for Today is NT$1,403.0 Mil.
Bioptik Technology (ROCO:4161) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bioptik Technology Market Cap Related Terms
Bioptik Technology Market Cap Historical Data
* Premium members only.
The historical data trend for Bioptik Technology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioptik Technology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioptik Technology Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioptik Technology's Market Cap distribution charts can be found below:
* The bar in red indicates where Bioptik Technology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bioptik Technology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioptik Technology (ROCO:4161) has a Market Cap of NT$1,375.6 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bioptik Technology and its competitors. According to the industry distribution chart, Bioptik Technology ranks #556 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 64.2%.
Is Bioptik Technology's Market Cap too high?
Bioptik Technology's current Market Cap is NT$1,375.6 Mil. Based on the distribution chart, Bioptik Technology ranks #556 out of 866 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bioptik Technology has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioptik Technology's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bioptik Technology ranks #556 out of 866 companies for Market Cap. This places Bioptik Technology in the lower half of its industry. The industry median Market Cap is 119.91. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 119.91, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bioptik Technology and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 119.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioptik Technology's current Market Cap is NT$1,375.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioptik Technology stock overvalued right now?
Based on GuruFocus' analysis, Bioptik Technology (ROCO:4161) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.79, compared to a current price of NT$23.00 — trading 17.2% below its estimated fair value. The current Market Cap is NT$1,375.6 Mil. Bioptik Technology's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Bioptik Technology (ROCO:4161), the current Market Cap is NT$1,375.6 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioptik Technology (ROCO:4161) Overvalued in 2026?
Based on GuruFocus' analysis, Bioptik Technology stock appears to be undervalued.
The current stock price of NT$23.00 is trading 17.2% below its estimated GF Value™ of NT$27.79.
GuruFocus considers Bioptik Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4161:
Market Cap: NT$1,375.6 Mil
GF Value™: NT$27.79 vs. price of NT$23.00 (17.2% below fair value)
No single metric tells the full story. See the ROCO:4161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioptik Technology Inc is a Taiwan-based company engaged in the research, development, production, and sale of medical devices and reagents. The company is also focused on developing skin care products and aims to engage in developing bioenergy, Astaxanthin, and Cellulose Bioethanol. It is involved in the business areas of Home care medical devices, Skincare- Its own brand, Dietary supplement OEM and ODM, Skincare- OEM and ODM, and Biodiesel. In the Home care business area, the company provides Easy Touch blood glucose monitoring, and blood cholesterol and uric acid monitoring systems, as well as its strips.
68GF Score
Get the complete analysis for ROCO:4161
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4161 has been successfully added to your 
